NET Patient Foundation Research Abstracts
NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in England using English cancer registry data, with an aim to also access Scottish, Welsh and Northern Irish cancer registry data to also get UK wide statistics.
We carried out four pieces of research in 2017, abstracts for which can be found below:
- The Incidence and Prevalence of Neuroendocrine Tumours in England.
- The 1- year survival rates for Neuroendocrine tumour patients in England.
- Metachronus primary cancers in Neuroendocrine tumour patients.
- Neuroendocrine Tumour patients experiences of support in the community setting across the treatment trajectory.
Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours
Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues – the role for specialist dietitians and nurses
- Assess what symptoms/side effects patients report on SSA’s.
- Assess the severity of symptoms/side effects reported by patients whilst on SSA’s.
- Produce recommendations on how to deal with symptoms commonly experienced by patients on SSA’s.
This study has been accepted to be published in the British Journal of Nursing.
Recent News
Professor Newell-Price, new President-elect at The Endocrine Society
Listen and Learn from Patients: An interview with Professor Newell-Price, new President-elect at The Endocrine Society "Trained by Titans of Clinical Endocrinology" John Newell-Price is Professor of Endocrinology at the University of Sheffield, and is an Honorary...
Episode 2 of the ‘Not Just NE Cancer Takeover Series’ Explores RareCan’s Innovative Research Platform
We are excited to announce that Episode 2 of the "Not Just NE Cancer Takeover Series" is now live! In this captivating episode, our Campaigns Lead, Lisa engages in a thought-provoking discussion with Andy Hall, Co-founder & Chief Scientific Officer of RareCan, a...
Join the Pathway Virtual Challenge and Support Neuroendocrine Cancer Research!
We are thrilled to announce the launch of the Pathway Virtual Challenge, an exciting nationwide event aimed at advancing neuroendocrine cancer research and making a real difference in the lives of those affected by this complex disease. Neuroendocrine Cancer UK...